$76.97 Million in Sales Expected for Amicus Therapeutics, Inc. (NASDAQ:FOLD) This Quarter

Wall Street analysts forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Rating) will post sales of $76.97 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Amicus Therapeutics’ earnings. The highest sales estimate is $78.05 million and the lowest is $76.20 million. Amicus Therapeutics posted sales of $66.40 million in the same quarter last year, which suggests a positive year over year growth rate of 15.9%. The company is scheduled to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Amicus Therapeutics will report full-year sales of $365.92 million for the current year, with estimates ranging from $365.37 million to $366.90 million. For the next year, analysts expect that the company will post sales of $513.57 million, with estimates ranging from $490.65 million to $536.49 million. Zacks’ sales averages are an average based on a survey of analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLDGet Rating) last released its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.15). Amicus Therapeutics had a negative net margin of 81.98% and a negative return on equity of 87.21%. The firm had revenue of $82.15 million during the quarter, compared to analysts’ expectations of $82.57 million. During the same quarter in the previous year, the firm posted ($0.27) EPS.

Several equities analysts recently issued reports on FOLD shares. StockNews.com started coverage on shares of Amicus Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating on the stock. SVB Leerink cut their price objective on shares of Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th. The Goldman Sachs Group started coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They issued a “neutral” rating on the stock. Finally, Cantor Fitzgerald cut their price objective on shares of Amicus Therapeutics from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, January 13th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $15.14.

In other Amicus Therapeutics news, COO Bradley L. Campbell sold 10,940 shares of the stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $10.00, for a total value of $109,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Margaret G. Mcglynn sold 15,000 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $6.99, for a total transaction of $104,850.00. Following the completion of the transaction, the director now owns 38,034 shares in the company, valued at $265,857.66. The disclosure for this sale can be found here. Insiders sold 39,172 shares of company stock worth $331,874 over the last quarter. Insiders own 2.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. raised its position in shares of Amicus Therapeutics by 155.7% during the 4th quarter. First Horizon Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 1,776 shares during the period. Parallel Advisors LLC grew its stake in Amicus Therapeutics by 1,173.1% during the fourth quarter. Parallel Advisors LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 3,097 shares in the last quarter. Dark Forest Capital Management LP grew its stake in Amicus Therapeutics by 1,967.5% during the third quarter. Dark Forest Capital Management LP now owns 4,838 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 4,604 shares in the last quarter. Copernicus Capital Management LLC purchased a new position in Amicus Therapeutics during the third quarter valued at $96,000. Finally, CIBC Asset Management Inc purchased a new position in Amicus Therapeutics during the third quarter valued at $101,000.

Shares of NASDAQ FOLD opened at $6.62 on Friday. Amicus Therapeutics has a 1 year low of $6.45 and a 1 year high of $12.63. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.09 and a quick ratio of 3.90. The company’s 50-day moving average is $8.59 and its 200 day moving average is $9.84. The stock has a market capitalization of $1.85 billion, a P/E ratio of -7.20 and a beta of 1.42.

About Amicus Therapeutics (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Stories

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.